How to Order     |    
Sign Up for Bi-Monthly E-News   
  Order Online
 
 
 
 

Blog Highlights

Some Questions and answers posted on a You Tube Video posted about Custodiol HTK

CUSTODIOL® HTK Solution for Myocardial Protection During an Aortic Valve Replacement Perfusionist Collette Calame answers some questions that were posted on this video.  Surgery performed by Dr. Timothy Trotter.  

Read full post...

Breaking News - FDA Investigates Safety of Cardioplegic Solutions Produced by NECC - BE SAFE! Use Custodiol HTK®!

Two transplant patients who received a solution produced by NECC to induce cardiac muscle paralysis during open heart surgery have subsequently developed the rare fungal meningitis.

Read full story here...

Aortic Translocation Operation - Single Dose Custodiol® Cardioplegia for Myocardial Protection

Since the operation requires a prolonged aortic cross clamp time, single dose Custodiol® cardioplegia was considered to be suitable for myocardial protection.

Watch the video here...

Ask The Experts Forum

An open forum for transplant professionals

This interactive forum is solely devoted to questions and expert answers from medical peers and professionals that have expertise in the organ preservation solution arena.

This interactive site provides peer to peer education. It allows you to post a question, answer a previously asked question should you know the answer, and is monitored for content and clarification purposes by an Organ Preservation Solution expert.
I have never had to re-operate on a liver transplant patient because of biliary complications since I've used Custodiol.
- Dr. Charles Miller, Cleveland Clinic
With Custodiol, the flush in the liver is more uniform and homogenous, providing better protection.
- Dr. Paulo Fontes, University of Pittsburgh
I use Custodiol HTK exclusively and my results are better than the national average.
- Dr. James Eason, University of Tennessee
Centers that have a lot of experience using HTK have excellent outcomes.
- Dr. John Fung, Cleveland Clinic
I now routinely use Custodiol for my more complicated cardiac surgical operations and have been uniformly impressed with all aspects of myocardial protection afforded by this agent.
- Dr. Joseph Cleveland, Jr., University of Colorado at Denver
We use Custodiol HTK solution to flush all our LDLT grafts and find it superior to other solutions at reperfusion.
- Dr. David Mulligan, Director, Transplant Center, Mayo Clinic
I have used Custodiol exclusively for the past decade in all living donor and cadaveric transplantation with excellent preservation and graft function.
- Dr. Juan Arenas, UT Southwestern Medical Center
 
 
 

Recent Studies
   
Crystalloid-Based Cardioplegia for Minimally Invasive Cardiac Surgery
Click here to read the full study
by Martin Misfeld, MD, PhD, and Piroze Davierwala, MD
   
   
Reducing Pediatric Live Transplant Complications: A Potential Roadmap for Transplant Quality Improvement Initiatives Within North America
Click here to read the full study
by M.J. Englesbe, B. Kelly, J.Goss, A. Fecteau, J. Mitchell, W. Andrews, G. Krapohl, J.C. Magee, G. Mazariegos, S. Horslen and J. Bucuvalas
   
   
New Randomized Kidney Study Reaffirms Custodiol's Protective Capabilities
Click here to read the full study
by O’Callaghan, J.M., et al
   
   
HTK Superior to LR in Preventing DGF – and, more Cost-Effective
Click here to read the full study
by Rofaiel, G. et al, #P-40
   
Read more studies...
   
   

Clearly Custodiol® Blog

Some Questions and answers posted on a You Tube Video posted about Custodiol HTK
CUSTODIOL® HTK Solution for Myocardial Protection During an Aortic Valve Replacement Perfusionist Collette Calame answers some questions that were posted on this video.  Surgery performed by Dr. Timothy Trotter.  
Read more.

Liver Transplant Outcomes in the United States : Effect of Preservation Solution John Fung, MD, PhD Cleveland Clinic
Dr. John Fung made this presentation in Germany a few months back.  I was just able to obtain a copy of his power point.  Finally some clear rationale and thinking behind a VERY flawed “database analysis” Fung-Berlin HTK Symposium slides 7-12
Read more.

One single antegrade dose of cold HTK cardioplegia is a safe and easy cardioprotective strategy in minimally invasive mitral valve surgery
One single antegrade dose of cold HTK cardioplegia is a safe and easy cardioprotective strategy in minimally invasive mitral valve surgery Carlo Savini, Sr., Giacomo Murana, Marco Di Eusanio, Sofia Martin Suarez, Sebastiano Castrovinci, Giuliano Jafrancesco, Andrea Castelli, Roberto Di Bartolomeo. Ospedale S.Orsola-Malpighi, Bologna, Italy. OBJECTIVE: Minimally invasive cardiac surgery (MICS) sometimes can be technically
Read more.

Crystalloid-Based Cardioplegia for Minimally Invasive Cardiac Surgery
Authors:  Martin Misfeld, MD, PhD, and Piroze Davierwala, MD With the ever-increasing popularity of minimally invasive (MI) cardiac surgery, procedures like aortic valve replacement, with or without concomitant  aortic surgery, and mitral and tricuspid valve procedures are now routinely performed through a minimal-access partial upper sternotomy and right anterolateral small thoracotomy, respectively, in our institution.
Read more.

New Video – New Options for Cardioplegia
http://www.ctsnet.org/ http://www.ctsnet.org/sections/videosection/videos/vg2013_newOptionsCardioplegia.html Dr. Samuel Weinstein Dr. Yoshiya Toyoda In this video, Tiffany Boyd-Hodgson, PhD, the Westfield Group’s Medical/Scientific Director, interviews two distinguished cardiothoracic surgeons, Dr. Samuel Weinstein and Dr. Yoshiya Toyoda, on their preferences and experiences in current cardioplegia options for adult and pediatric heart surgery. Drs. Weinstein and Toyoda share their insights on the
Read more.

Which Is the Better Option During Neonatal Cardiopulmonary Bypass: HTK Solution or Cold Blood Cardioplegia?
Which Is the Better Option During Neonatal Cardiopulmonary Bypass: HTK Solution or Cold Blood Cardioplegia? Chen Y, Liu J, Li S, Li W, Yan F, Sun P, Wang H, Long C. Source From the *Department of Cardiopulmonary Bypass, ††Department of Pediatric Cardiac Surgery, and ‡‡Department of Anesthesiology, Fuwai Hospital & National Center for Cardiovascular Diseases,
Read more.

“like” Custodiol on Facebook for your chance to win!!!
It’ so easy – Like us on Facebook  and you will be entered to win a Kindle Fire.  One winner will be chosen from all  “likes” by December 1st. https://www.facebook.com/pages/Custodiol-HTK/158221620882331      
Read more.

“No question Custodiol (Bretschneider’s solution, HTK) has stood the test of time”
We found this post under perfusion.com http://lists.perfusion.com/read/messages?id=10952
Read more.

Custodiol HTK noted under Best Practices
Englesbe-Reducing Ped Liver Tx Complications Improvement Initiatives 9-12 Check out Step 3b: Best Practice Report: Biliary Complications Liver flush with histidine-tryptophan-ketoglutarate (HTK) solution. American Journal of Transplantation 2012; 12: 2301–2306 Reducing Pediatric Liver Transplant Complications: A Potential Roadmap for Transplant Quality Improvement Initiatives Within North America  M. J. Englesbea,∗, B. Kellyb , J. Gossc , A. Fecteaud , J.
Read more.

New Study accepted by the FDA – Custodiol-HTK Cardioplegia
New Study accepted by the FDA from Marc Sakwa, MD, William Beaumont Hospitals. The purpose of the study is to demonstrate that Custodiol-HTK is not inferior to cold cardioplegic solution in patients undergoing cardiovascular surgery requiring cardioplegic arrest. http://clinicaltrials.gov/ct2/show/NCT01681095?cond=
Read more.
 
 
 
 

Custodiol® in the News
 
New Video on CTSNET.org
Drs. Weinstein and Toyoda share their insights on the ever-evolving concept of cardioplegia, discussing options such as blood cardioplegia and Custodiol® HTK. They provide valuable perspectives on what works in their respective operating rooms and how it may be relevant to other cardiothoracic surgeons looking for new options in cardioplegia. View the video here.
 
 
New Study Underway
A new study is currently recruiting participants under the title Custodiol-HTK Solution as a Cardioplegic Agent - A Prospective Non-Inferiority Randomized Clinical Trial. For more information, visit ClinicalTrials.gov.
 
 
Custodiol® HTK used in less-than-perfect organs.
Donor demographics are changing and the need for transplant organs far outnumbers donations. Surgeons are turning to organs donated from nontraditional sources.
Read more in USATODAY.
 
 
Female Hand Transplant Story
The first hand transplant in the U.S. done on a woman and is the first done at a government defense facility. This honor belongs to San Antonio! According to a spokesperson at the San Antonio OPO, Custodiol® HTK is all they stock for Organ Preservation solution, Custodiol® is what was used to preserve!
Read more.
 
 
Double Arm Transplant
Five teams of medical professionals worked to graft donor arms onto the body of a German farmer in the world's first complete double arm transplant.
Read the full story.
 
 
Organ Transplant Statistics for the United States
The United Network for Organ Sharing (UNOS), a nonprofit charitable organization, maintains the nation's organ transplant waiting list.
Read more.
 
 

Ask The Experts
 
An open forum for transplant professionals at www.QuestionSolution.com.
 
Visit our interactive forum which provides a platform for questions and expert answers from your medical peers and professionals that have expertise in the organ preservation solution arena. We believe that peer to peer education is "essential."
 
     
 
  Home   |   About Custodiol®   |   Resources   |   Prescribing Information   |   References   |   Videos   |   Glossary   |   Clearly Custodiol® Blog   |   Contact Us  
 
  CUSTODIOL® HTK Solution is indicated for perfusion and flushing of donor kidneys, liver, pancreas and heart prior to removal from the donor or immediately after removal from the donor. The solution is left in the organ vasculature during hypothermic storage and transportation (not for continuous perfusion) to the recipient. Read More...  
     
  © Essential Pharmaceuticals, LLC   |   Site Map   |   Disclaimer  
     
  Custodiol® HTK is a Registered Trademark of Dr. Franz Köhler Chemie GmbH used under license by Essential Pharmaceuticals, LLC.